Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.83 |
| ▸ | HEXA | P06865 | 13/20 | 0.80 |
| ▸ | HEXB | P07686 | 13/20 | 0.80 |
| ▸ | OGA | O60502 | 2/20 | 0.80 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14537686 | 0.94 | SIRT1 (0.79) | SIRT1HEXAHEXBOGACYP1B1 | |
| Elinafide SCHEMBL6256967 | 0.91 | SIRT1 (1.00) | SIRT1HEXAHEXBOGANR1I2 | |
| SCHEMBL8396162 | 0.91 | SIRT1 (0.94) | SIRT1HEXAHEXBOGANR1I2 | |
| Elinafide SCHEMBL29441732 | 0.91 | SIRT1 (1.00) | SIRT1HEXAHEXBOGANR1I2 | |
| Elinafide SCHEMBL19067 | 0.91 | SIRT1 (1.00) | SIRT1HEXAHEXBOGANR1I2 | |
| SCHEMBL14548886 | 0.90 | SIRT1 (0.82) | SIRT1HEXAHEXBOGACYP1B1 | |
| SCHEMBL4408773 | 0.89 | HEXA (1.00) | SIRT1HEXAHEXBOGA | |
| SCHEMBL31011151 | 0.89 | HEXA (1.00) | SIRT1HEXAHEXBOGA | |
| SCHEMBL14537685 | 0.89 | SIRT1 (0.84) | SIRT1HEXAHEXBOGACYP1B1 | |
| SCHEMBL14548885 | 0.89 | SIRT1 (0.79) | SIRT1HEXAHEXBOGACYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287484-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287484-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | SIRT1 1700/4885HEXA 286/4885HEXB 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.